PAA
CRSP icon

Peregrine Asset Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Peregrine Asset Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,647
Closed -$267K – 140
2021
Q2 		$267K Buy
+1,647
New +$200K 0.12% 102

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Peregrine Asset Advisers's CRSP Position: Q3 2021 in Review

Peregrine Asset Advisers sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 1,647 shares — an estimated $267K sold.

Peregrine Asset Advisers first reported a position in CRSP in Q2 2021 and held it in 1 quarter. The position peaked at $267K in Q2 2021. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Peregrine Asset Advisers reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Peregrine Asset Advisers sold 1,647 CRISPR Therapeutics shares in Q3 2021, an estimated $267K.
  • Peregrine Asset Advisers first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 1 quarter.
  • Peregrine Asset Advisers's CRISPR Therapeutics position peaked at $267K in Q2 2021.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Peregrine Asset Advisers's 13F filing for Q3 2021, filed 9 Nov 2021.